We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Partnership to Simplify Complex DNA Microarray Analyses

By LabMedica International staff writers
Posted on 14 Jul 2011
A partnership between American and British biotech companies will automate and simplify the complex and error-prone manual steps previously required for performing DNA microarray analyses.

BlueGnome (Cambridge, United Kingdom) has announced the signing of a supply agreement with SciGene (Sunnyvale, CA, USA). More...
SciGene will manufacture BlueGnome’s new range of ClearHyb hybridization and wash systems.

Previously SciGene had noted that BlueGnome’s recommended manual labeling, hybridization, and posthybridization processing methods for its CytoChip test required a collection of laboratory equipment and supplies including staining dishes, slide boxes, stirrers, Coplin jars, a water bath, and an oven that need to be collected, cleaned, and assembled for each run. Once set up, the procedure was technically challenging with many handling steps including the use of seven different washes with careful monitoring of buffer temperatures. The complexity of the methods provided multiple entry points for variability that could lead to ambiguous patient results and a higher cost per test.

The new partnership was designed to eliminate this ambiguity by automating and simplifying the complex and error-prone manual steps from sample preparation through slide processing for improved test reliability and lowered cost.

Nick Haan, CEO of BlueGnome, said, “Time to market is a major issue for new laboratories that wish to establish and evolve their microarray-based services. With sales to 39 countries so far this year, we find that new laboratories are increasingly looking for a complete turnkey solution, including laboratory hardware, which enables their newly trained scientists to deliver the highest quality results in the shortest possible timeframe. We have long recommended SciGene products as the best available solution for hybridization and washing of our microarrays and are excited to be working with them to strengthen this relationship with new ClearHyb products.”

Dr. Jim Stanchfield, president and CEO of SciGene, said, “We are pleased with our partnership whereby SciGene technology will be used to simplify the microarray workflow used with BlueGnome’s array solutions that will enhance the reproducibility of these assays and their customers’ laboratory productivity.”

Related Links:
BlueGnome
SciGene


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.